Physician profile
Thomas E Mandat
NPI 1881792794
$1,795.83
in general payments reported to CMS, 2019-2025
37 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2021: $412 · 2022: $397 · 2023: $315 · 2024: $85.51 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.72 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.63 | 2023-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company Ltd. | $164.62 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $162.52 | 2021 | |
| Janssen Pharmaceuticals, INC | $159.22 | 2019-2022 | |
| Allergan, INC. | $117.39 | 2019 | |
| Avanir Pharmaceuticals, INC. | $85.50 | 2021 | |
| Mannkind Corporation | $85.00 | 2025 | |
| Sk Life Science, INC. | $75.82 | 2025 | |
| Lilly USA, LLC | $66.92 | 2021-2025 | Amyvid, Kisunla |
| Pfizer INC. | $65.66 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.38 | 2022-2023 | |
| Abbvie INC. | $41.83 | 2021-2023 | |
| Novo Nordisk INC | $38.45 | 2024-2025 | |
| Ucb, INC. | $38.35 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.71 | 2024-2025 | Jardiance |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $29.90 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $28.75 | 2023-2024 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $28.61 | 2022-2024 | Trelegy Ellipta |
| Melinta Therapeutics, LLC | $24.76 | 2019 | |
| Neurocrine Biosciences, INC. | $20.89 | 2025 | |
| Dexcom, INC. | $20.28 | 2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $19.62 | 2025 | Vowst |
| Cmp Pharma, INC. | $17.20 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.16 | 2023 | |
| Urovant Sciences INC | $16.78 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.17 | 2022 | |
| Amgen INC. | $15.14 | 2025 | Repatha |
| Hikma Pharmaceuticals USA | $14.24 | 2021 | |
| Eyevance Pharmaceuticals LLC | $14.24 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.72 | 2023 | Gvoke Hypopen |
| Jazz Pharmaceuticals INC. | $13.67 | 2021 | |
| Smith+Nephew, INC. | $13.44 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.26 | 2023 | Austedo Xr |
| Nestle Healthcare Nutrition INC. | $13.13 | 2022 | |
| Evoke Pharma, INC. | $12.74 | 2023 | Gimoti |
| Eisai INC. | $11.78 | 2021 | |
| Astellas Pharma US INC | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mandat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.